Title: Neuroprotective Therapy in Optic Nerve Diseases: Advanced Treatments and Future Therapies

Description: Explore advanced neuroprotective therapy for optic nerve diseases, including mitochondrial protection, antioxidants, neurotrophic factors, stem cells, gene therapy and current clinical trials.

Focus Keyword: Neuroprotective therapy in optic nerve diseases

Related Keywords: optic nerve treatment, optic nerve regeneration, retinal ganglion cell protection, neuroprotection in glaucoma, mitochondrial therapy, stem cell therapy, optic nerve gene therapy

---

Introduction

The optic nerve is the major communication pathway between the eye and the brain. It contains the axons of retinal ganglion cells (RGCs), which transmit visual information from the retina to the visual centers of the brain.

Optic nerve damage can occur in several conditions, including glaucoma, optic neuritis, ischemic optic neuropathy, traumatic optic neuropathy, compressive optic neuropathy and inherited optic neuropathies.

One of the major challenges in treating optic nerve disease is that damaged retinal ganglion cells have very limited ability to regenerate. Once substantial RGC and axonal loss has occurred, conventional treatment generally cannot restore the lost neural connections. Therefore, modern research is increasingly focusing on neuroprotection—keeping surviving neurons alive—and neuroregeneration—attempting to restore damaged neurons and axons.

1. What Is Neuroprotective Therapy?

Neuroprotection refers to treatments designed to prevent or slow the death of retinal ganglion cells and the degeneration of their axons.

The basic concept is:

Optic nerve injury → RGC stress → axonal dysfunction → cellular damage → RGC death → permanent visual loss

Neuroprotective treatment attempts to interrupt this pathway before irreversible neuronal loss occurs.

In glaucoma, for example, lowering intraocular pressure (IOP) remains the established strategy for slowing disease progression. However, researchers are investigating treatments that could protect RGCs through mechanisms independent of IOP reduction, particularly because progression can continue in some patients despite adequate IOP control.

Main goals of neuroprotection

• Preserve retinal ganglion cells
• Maintain axonal integrity
• Protect mitochondrial function
• Reduce oxidative stress
• Control harmful neuroinflammation
• Prevent apoptosis
• Improve neuronal metabolism
• Maintain synaptic function
• Preserve visual field and visual function

2. Mechanisms of Optic Nerve Damage

Optic nerve damage is not caused by a single mechanism. Multiple cellular and molecular pathways can interact.

Major mechanisms include:

1. Mechanical stress
2. Ischemia and reduced blood supply
3. Mitochondrial dysfunction
4. Oxidative stress
5. Neuroinflammation
6. Excitotoxicity
7. Impaired axonal transport
8. Neurotrophic factor deprivation
9. Apoptosis
10. Glial-cell dysfunction

2.1 Mechanical and Axonal Stress

In glaucoma, mechanical stress at the optic nerve head and lamina cribrosa can disturb the axons of retinal ganglion cells.

This can interfere with:

• Axonal transport
• Mitochondrial function
• Nutrient transport
• Neurotrophic signaling

Damage to axons can ultimately initiate pathways leading to RGC death.

2.2 Ischemia and Vascular Dysfunction

Retinal ganglion cells require continuous oxygen and nutrients.

Reduced perfusion or vascular dysregulation can contribute to:

• ATP depletion
• Mitochondrial dysfunction
• Oxidative stress
• Axonal injury
• Cellular death

This is particularly important in ischemic optic neuropathy and may also contribute to optic nerve vulnerability in glaucoma.

2.3 Oxidative Stress

Oxidative stress occurs when the production of reactive oxygen species (ROS) exceeds the body's antioxidant defenses.

Excess ROS can damage:

• DNA
• Proteins
• Lipid membranes
• Mitochondria
• Axonal structures

Recent research continues to investigate oxidative stress as an important component of RGC injury and possible target for neuroprotective treatment.

3. Neuroprotection vs. Neuroregeneration

These two terms are related but fundamentally different.

Neuroprotection

Goal: Keep existing retinal ganglion cells alive.

Examples of research approaches include:

• Mitochondrial protection
• Antioxidant therapy
• Anti-inflammatory strategies
• Neurotrophic factors
• Anti-apoptotic approaches

Neuroregeneration

Goal: Restore damaged neurons or encourage surviving RGCs to regrow their axons.

Potential approaches include:

• Gene therapy
• Stem-cell therapy
• Growth factors
• Electrical stimulation
• Molecular manipulation of regenerative pathways
• Biomaterials and scaffolds

The mature central nervous system presents major barriers to axonal regeneration, including inhibitory molecular environments, glial scarring and limited intrinsic regenerative capacity of mature RGCs.

4. Mitochondrial Protection

Mitochondria are often described as the energy-producing organelles of cells. Retinal ganglion cells have high metabolic requirements because they maintain long axons extending from the retina into the brain.

Mitochondrial dysfunction may result in:

↓ ATP production → ↑ oxidative stress → impaired axonal transport → neuronal dysfunction → RGC death

Research therefore investigates ways to:

• Maintain mitochondrial membrane potential
• Improve cellular energy production
• Reduce mitochondrial ROS
• Prevent mitochondrial fragmentation
• Improve mitochondrial transport along axons
• Support mitochondrial quality-control mechanisms

A 2026 review highlights mitochondrial dysfunction as an important therapeutic target and describes emerging approaches such as intercellular mitochondrial transfer, including investigation of mesenchymal stem cells as potential mitochondrial donors. Much of this evidence remains experimental.

Why mitochondria are important in optic nerve disease

The optic nerve contains extremely long axons. These axons require large amounts of energy for:

• Ion transport
• Action potential propagation
• Axonal transport
• Maintenance of membrane potential
• Cellular repair

Therefore, mitochondrial failure can have serious consequences for RGC survival.

5. Antioxidant and Anti-Inflammatory Approaches

5.1 Antioxidant Therapy

Antioxidants attempt to reduce the damaging effects of excessive reactive oxygen species.

Potential targets include:

• Superoxide
• Hydrogen peroxide
• Lipid peroxidation
• Mitochondrial ROS

Research has investigated both systemic and targeted antioxidant strategies.

However, an important distinction must be made: experimental evidence of antioxidant benefit does not automatically mean that a particular supplement or antioxidant is a proven treatment for optic nerve disease.

Recent reviews continue to report a gap between encouraging preclinical findings and successful clinical translation.

5.2 Anti-Inflammatory Therapy

Neuroinflammation involves interactions between:

• Microglia
• Astrocytes
• Müller glial cells
• Cytokines
• Complement pathways
• Retinal ganglion cells

Initially, inflammation can be part of a protective response. However, persistent or excessive inflammatory signaling may contribute to neuronal damage.

Potential therapeutic targets include:

• Pro-inflammatory cytokines
• Microglial activation
• Complement pathways
• Oxidative-inflammatory signaling
• Glial responses

The challenge is to suppress harmful chronic inflammation without eliminating beneficial repair mechanisms.

6. Neurotrophic Factors

Neurotrophic factors are naturally occurring proteins that support neuronal:

• Survival
• Growth
• Differentiation
• Axonal maintenance
• Synaptic function

Important factors investigated in optic nerve disease include:

Brain-Derived Neurotrophic Factor — BDNF

BDNF supports neuronal survival and signaling through TrkB receptors.

Ciliary Neurotrophic Factor — CNTF

CNTF has attracted considerable interest because experimental studies have shown effects on RGC survival and regeneration.

Nerve Growth Factor — NGF

NGF is another neurotrophic factor involved in neuronal survival and signaling.

The delivery problem

One major challenge is that neurotrophic factors can be cleared relatively quickly.

Therefore, researchers are developing:

• Sustained-release implants
• Encapsulated cell technology
• Gene therapy
• Nanoparticle delivery
• Viral-vector delivery

Research reviews have specifically highlighted sustained neurotrophin delivery as a potential way to overcome the limitations of short-lived growth-factor therapy.

7. Anti-Apoptotic Therapy

Apoptosis is programmed cell death.

When RGCs are exposed to prolonged stress, signaling pathways can activate apoptosis.

A simplified pathway is:

Cellular stress → mitochondrial dysfunction → caspase activation → apoptosis → RGC loss

Researchers are studying molecules that interfere with these pathways.

Potential strategies include:

• Caspase inhibition
• Mitochondrial stabilization
• Anti-apoptotic proteins
• Modulation of cell-survival pathways

The objective is not simply to keep a damaged cell alive temporarily, but to maintain a functional and healthy neuron.

8. Stem-Cell–Based Approaches

Stem-cell therapy is one of the most exciting areas of regenerative ophthalmology.

Researchers are investigating whether stem cells could help optic nerve disease through two broad mechanisms.

8.1 Neuroprotective effects

Stem cells may release biological signals that influence:

• Inflammation
• Oxidative stress
• Neuronal survival
• Tissue repair
• Growth-factor signaling

8.2 Cell replacement

Another goal is to generate new retinal ganglion cells and integrate them into the damaged retina.

Potential sources include:

• Mesenchymal stem cells
• Retinal progenitor cells
• Embryonic stem-cell-derived cells
• Induced pluripotent stem-cell-derived cells

However, successful RGC replacement requires much more than producing new cells.

The cells must:

1. Survive.
2. Integrate into the retina.
3. Develop appropriate connections.
4. Extend axons through the optic nerve.
5. Reach the correct brain targets.
6. Form functional synapses.

These remain major scientific challenges.

9. Gene Therapy for Optic Nerve Protection and Regeneration

Gene therapy aims to modify cellular function by delivering genetic material to target cells.

Potential applications include:

• Correcting disease-causing mutations
• Increasing neurotrophic signaling
• Activating regenerative pathways
• Protecting mitochondria
• Modifying inflammatory pathways
• Increasing RGC survival

Inherited mitochondrial optic neuropathies such as Leber hereditary optic neuropathy (LHON) have been important targets for gene-therapy research.

For example, ClinicalTrials.gov records include studies of gene therapy targeting the mitochondrial ND4 mutation associated with LHON. Several earlier studies are completed, while newer studies continue to investigate dosing and treatment strategies.

10. Electrical Stimulation and Neurorehabilitation

Another emerging approach is electrical stimulation of the visual system.

The concept is that controlled electrical stimulation may influence neuronal activity and potentially promote survival or regenerative responses.

Research is examining whether stimulation can:

• Activate surviving RGCs
• Improve neuronal signaling
• Influence neuroplasticity
• Support visual function

A ClinicalTrials.gov study initiated in 2026 is investigating repetitive transcranial alternating-current stimulation for optic neuropathies, with glaucoma as the primary listed condition.

This remains an investigational approach rather than routine treatment.

11. Current Clinical Trials and Emerging Treatments

The field of optic nerve neuroprotection is moving from laboratory research toward human clinical trials, but many approaches remain experimental.

Metformin as a potential neuroprotective treatment

One interesting example is metformin, a drug traditionally used to treat type 2 diabetes.

A ClinicalTrials.gov study, NCT05426044, is recruiting participants to investigate whether metformin can slow structural and functional progression in primary open-angle glaucoma independently of its IOP-lowering effects. The study plans to compare metformin with placebo over 24 months and monitor RNFL/GCIPL thickness and visual-field changes.

Importantly, this does not mean metformin is currently an approved neuroprotective treatment for glaucoma. The clinical trial is testing the hypothesis.

Topical insulin

A newer study, NCT07619482, registered in 2026, is investigating topical insulin in glaucoma with neuroprotection listed among its research concepts.

Prostaglandin analogues

Another 2026 study, NCT07074782, is investigating whether prostaglandin analogue eye drops may have direct effects on RGC survival beyond their established IOP-lowering action.

Gene therapy for LHON

Newer trials continue to investigate gene therapy for mitochondrial ND4-associated LHON. For example, the REVISE study (NCT07303296) began in 2026 and is evaluating different doses of GS010 through intravitreal administration.

12. Nanotechnology and Targeted Drug Delivery

One of the biggest problems in neuroprotective therapy is delivering therapeutic molecules to the correct cells at an adequate concentration for a sufficient period.

Nanotechnology may potentially help by providing:

• Controlled drug release
• Improved tissue penetration
• Targeted delivery
• Reduced systemic exposure
• Protection of unstable molecules

Possible platforms include:

• Nanoparticles
• Liposomes
• Biodegradable polymers
• Hydrogel systems
• Nanocarriers

These technologies are still largely under investigation for optic nerve neuroprotection.

13. OCT and Imaging in Neuroprotective Treatment

Modern imaging is essential for determining whether a neuroprotective therapy is actually working.

Important clinical measurements include:

OCT

• RNFL thickness
• Ganglion cell-inner plexiform layer thickness
• Optic nerve head parameters

Visual field testing

• Mean deviation
• Pattern standard deviation
• Visual-field progression

Optic nerve photography

• Disc appearance
• Neuroretinal rim
• Progressive structural changes

These measurements help researchers determine whether a treatment is slowing structural or functional deterioration.

14. Major Challenges in Optic Nerve Neuroprotection

Despite promising research, several problems remain.

1. Irreversible neuronal loss

Once large numbers of RGCs have died, simply protecting surviving cells cannot restore the lost neurons.

2. Axonal regeneration

Even if an RGC survives, its axon must travel from the retina through the optic nerve and reach the appropriate brain target.

3. Complex disease mechanisms

Optic nerve diseases have different causes, so one treatment may not work for every disease.

4. Drug delivery

The therapeutic molecule must reach the appropriate cells at the correct dose and for an adequate duration.

5. Long-term safety

Gene and cell therapies require careful assessment of:

• Inflammation
• Immune reactions
• Abnormal cell growth
• Tumor risk
• Retinal toxicity
• Long-term biological effects

Stem-cell reviews emphasize challenges including cell survival, correct differentiation, delivery, integration and the potential risk associated with undifferentiated cells.

15. Future of Optic Nerve Treatment

The future may involve a combination therapy approach rather than a single treatment.

A possible future strategy could combine:

IOP control + mitochondrial protection + anti-inflammatory therapy + neurotrophic support + gene therapy + regenerative treatment

Researchers are also exploring:

• Precision medicine
• AI-assisted progression prediction
• Gene editing
• Mitochondrial transfer
• Advanced drug-delivery systems
• Cell replacement
• Axonal regeneration
• Remyelination
• Electrical stimulation
• Combination neuroprotective therapies

Recent reviews emphasize that successful regeneration will likely require addressing both intrinsic limitations within RGCs and external inhibitory factors surrounding injured axons.

16. Role of Optometrists in Neuroprotective Care

Optometrists can play an important role in the early detection and monitoring of optic nerve disease.

Key responsibilities include:

• Comprehensive visual acuity assessment
• IOP measurement
• Optic nerve head evaluation
• OCT interpretation
• RNFL and ganglion-cell analysis
• Visual-field assessment
• Monitoring progression
• Patient education
• Referral to an ophthalmologist when required
• Monitoring treatment adherence

For glaucoma especially, identifying structural progression on OCT and functional progression on visual fields can help clinicians recognize disease progression early.

At present, most true neuroregenerative and many neuroprotective approaches remain investigational. Standard treatment still depends on the underlying optic nerve disease—for example, IOP reduction remains central to glaucoma management. Current research is attempting to move beyond simply controlling risk factors toward directly preserving or restoring retinal ganglion cells.

Conclusion

Neuroprotective therapy in optic nerve diseases represents one of the most promising areas of modern ophthalmic research.

The central goal is to prevent retinal ganglion cells from reaching the point of irreversible death. Mitochondrial protection, antioxidant strategies, control of neuroinflammation, neurotrophic factors and anti-apoptotic approaches are being investigated to preserve existing neurons.

At the same time, stem-cell therapy, gene therapy, electrical stimulation and axonal regeneration strategies are attempting to go one step further by restoring damaged neural tissue.

The major challenge is that the optic nerve is part of the central nervous system, and successful visual restoration requires not only survival or regeneration of RGCs but also accurate axonal reconnection with the brain. Consequently, the future of optic nerve treatment will likely depend on combining neuroprotection with regeneration, advanced drug delivery, molecular therapies and precision monitoring.

The research pipeline is active in 2026, with clinical studies investigating approaches such as metformin, topical insulin, electrical stimulation and gene therapy. However, these should be considered research treatments rather than established routine therapies until adequate clinical evidence demonstrates safety and effectiveness.